文献速递心力衰竭与心肌病冠心病血脂与心血管预防

NAD+代谢在心脏健康、衰老与疾病中的作用

NAD+ Metabolism in Cardiac Health, Aging, and Disease.
PubMed 文献 · Circulation · 2021-11-29

本文综述了烟酰胺腺嘌呤二核苷酸(NAD+)在心脏能量与氧化还原稳态、DNA修复及蛋白去乙酰化中的作用,指出NAD+水平随正常衰老、肥胖和高血压下降,而补充NAD+前体在临床前模型中可改善代谢健康、降低血压并改善多种心血管疾病。文章批判性讨论了心肌细胞特异性NAD+代谢回路,比较了不同NAD+前体的临床前疗效,并提出了关于NAD+补充临床试验设计的待解决问题。

要点

  • NAD+水平随衰老、肥胖和高血压下降,补充NAD+前体在临床前模型中可改善代谢健康并降低血压。
  • 实验性升高NAD+可改善动脉粥样硬化、缺血性、糖尿病性、心律失常性、肥厚性或扩张型心肌病及不同形式的心力衰竭。
  • 射血分数保留的心力衰竭等难治性心脏病患者可能从NAD+前体治疗中获益,但需进一步临床试验验证。

核心结论

  • NAD+补充或超生理性升高在临床前模型中对多种心脏疾病具有保护作用,但最佳临床试验设计尚待明确。

研究设计与样本

  • 本文为综述,批判性讨论了心肌细胞特异性NAD+代谢回路,比较了不同NAD+前体的临床前疗效,并提出了临床试验设计的待解决问题。

主要发现

  • NAD+池随正常衰老、肥胖和高血压下降,这些均为心血管疾病的主要风险因素。
  • 在临床前模型中,NAD+补充可延长健康寿命、避免代谢综合征并降低血压。
  • 实验性升高NAD+可改善动脉粥样硬化、缺血性、糖尿病性、心律失常性、肥厚性或扩张型心肌病以及不同形式的心力衰竭。

临床怎么用

  • 射血分数保留的心力衰竭等目前难治性心脏病患者可能从NAD+前体给药中获益。
  • NAD+中心治疗的发展将依赖于对NAD+代谢精细调控的技术和概念进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nicotinamide adenine dinucleotide (NAD+) is a central metabolite involved in energy and redox homeostasis as well as in DNA repair and protein deacetylation reactions. Pharmacological or genetic inhibition of NAD+-degrading enzymes, external supplementation of NAD+ precursors, and transgenic overexpression of NAD+-generating enzymes have wide positive effects on metabolic health and age-associated diseases. NAD+ pools tend to decline with normal aging, obesity, and hypertension, which are all major risk factors for cardiovascular disease, and NAD+ replenishment extends healthspan, avoids metabolic syndrome, and reduces blood pressure in preclinical models. In addition, experimental elevation of NAD+ improves atherosclerosis, ischemic, diabetic, arrhythmogenic, hypertrophic, or dilated cardiomyopathies, as well as different modalities of heart failure. Here, we critically discuss cardiomyocyte-specific circuitries of NAD+ metabolism, comparatively evaluate distinct NAD+ precursors for their preclinical efficacy, and raise outstanding questions on the optimal design of clinical trials in which NAD+ replenishment or supraphysiological NAD+ elevations are assessed for the prevention or treatment of major cardiac diseases. We surmise that patients with hitherto intractable cardiac diseases such as heart failure with preserved ejection fraction may profit from the administration of NAD+ precursors. The development of such NAD+-centered treatments will rely on technological and conceptual progress on the fine regulation of NAD+ metabolism.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Abdellatif M, Sedej S, Kroemer G, et al. NAD+ Metabolism in Cardiac Health, Aging, and Disease. Circulation. 2021. PMID: 34843394. doi:10.1161/CIRCULATIONAHA.121.056589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。